-
-
-
-
-
-
-
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
-
-
-
-
-
-
-
Pfizer (PFE) PT Lowered to $35 at Guggenheim
-
-
-
-
-
-
-
Pfizer lung cancer drug misses survival goal in Phase 3 trial
-
-
-
-
-
-
-
Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
-
-
-
-
-
-
-
Pfizer's BRAFTOVI regimen shows improved survival in colorectal cancer
-
-
-
-
-
-
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
-
-
-
-
-
-
Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
-
1,224,140 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

